GH Research Presents Trial Findings at ICPR Conference

GH Research is the current title holder of Most Secretive Psychedelic Company. Despite being one of the industry’s market cap leaders, the firm has done close to zero media appearances and puts out the bare minimum when it comes to announcements and company updates.

So as a public service, we’re sharing the presentation the company released this week. Its data related to their Phase 1/2 clinical trial of GH001, and was presented at the Interdisciplinary Conference on Psychedelic Research on Sep 22nd.

See below for some highlights and click here for the full presentation.

We’ll have our science writer take a deeper dive into the data. Stay tuned for more.

Interested in more on GH Research? Check out A Look at GH Research’s Financial and Business Results